Clinical data
AHFS/ International Drug Names
MedlinePlus a682619
Routes of
ATC code R06AE04 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
CAS Number 82-93-9 YesY
PubChem (CID) 2710
ChemSpider 2609 YesY
ECHA InfoCard 100.001.315
Chemical and physical data
Formula C18H21ClN2
Molar mass 300.826 g/mol
3D model (Jmol) Interactive image

Chlorcyclizine (Di-Paralene, Mantadil, Pruresidine, Trihistan) is a first-generation antihistamine of the phenylpiperazine class marketed in the United States and certain other countries.[1][2][3] It is used primarily to treat allergy symptoms such as rhinitis, urticaria, and pruritus, and may also be used as an antiemetic.[1][2][3] In addition to its antihistamine effects, chlorcyclizine also has some anticholinergic, antiserotonergic, and local anesthetic properties.[4][5] It also has been studied as a potential treatment for hepatitis C.[6][7]

See also


  1. 1 2 Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  2. 1 2 David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  3. 1 2 Hall, Judith A.; Morton, Ian (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.
  4. Dorland Staff (2008). Dorland Dictionnaire Medical Bilingue Francais-anglais / Anglais-francais: + E-book a Telecharger (French Edition). Elsevier (Educa Books). ISBN 2-84299-899-5.
  5. Rogóz Z, Skuza G, Sowińska H (November 1981). "The effect of the antihistaminic drugs on the central action of 5-hydroxytryptophan in mice". Polish Journal of Pharmacology and Pharmacy. 33 (4): 459–65. PMID 6120505.
  6. He, S.; Lin, B.; Chu, V.; Hu, Z.; Hu, X.; Xiao, J.; Wang, A. Q.; Schweitzer, C. J.; Li, Q.; Imamura, M.; Hiraga, N.; Southall, N.; Ferrer, M.; Zheng, W.; Chayama, K.; Marugan, J. J.; Liang, T. J. (2015). "Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection". Science Translational Medicine. 7 (282): 282ra49. doi:10.1126/scitranslmed.3010286.
  7. Chamoun-Emanuelli, Ana Maria; Pecheur, Eve-Isabelle; Chen, Zhilei (July 2014). "Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus". Antiviral Research. 109: 141–148. doi:10.1016/j.antiviral.2014.06.014.

This article is issued from Wikipedia - version of the 9/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.